Characterizing Granulocytopenia Associated with Thiamazole in Patients with Hyperthyroidism Based on Real‐World Data from the MID‐NET in Japan
Open Access
- 31 January 2023
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 113 (4) , 924-931
Abstract
Despite the requirement of routine blood tests during thiamazole treatment in Japan, granulocytopenia among patients treated with thiamazole has been occasionally reported to the Pharmaceuticals and Medical Devices Agency (PMDA). To characterize granulocytopenia in patients with thiamazole in Japan, the effects of routine blood tests were examined in a cohort of new users of thiamazole or propylthiouracil utilizing the MID‐NET. The occurrence of granulocytopenia (neutrophil count ≤ 1,500/μL) in a given period was compared between patients with and without blood test results prior to the period. The trend in neutrophil count during thiamazole treatment was also compared between patients with and without granulocytopenia. A nested case–control study based on the cohort was conducted to identify potential risk factors for granulocytopenia during thiamazole treatment. In the new user cohort including 4,371 patients treated with thiamazole, the occurrence of granulocytopenia in patients who had undergone blood tests at all previous periods was similar or higher than that among those who had not undergone blood test in all previous periods (e.g., adjusted odds ratio in period 2 was 1.63). The neutrophil count was relatively lower in the group of patients with granulocytopenia even before the occurrence of granulocytopenia. In a nested case–control study, an upward tendency of the risk was observed when a patient was co‐prescribed anti‐arrhythmic drugs or antiulcer drugs with thiamazole. The characteristics of granulocytopenia during thiamazole treatment elucidated in this study should be recognized in clinical practice for the proper use of thiamazole.Keywords
This publication has 9 references indexed in Scilit:
- Establishment of the MID‐NET® medical information database network as a reliable and valuable database for drug safety assessments in JapanPharmacoepidemiology and Drug Safety, 2019
- The utilization and challenges of Japan's MID‐NET® medical information database network in postmarketing drug safety assessments: A summary of pilot pharmacoepidemiological studiesPharmacoepidemiology and Drug Safety, 2019
- 2018 European Thyroid Association Guideline for the Management of Graves’ HyperthyroidismEuropean Thyroid Journal, 2018
- 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of ThyrotoxicosisThyroid®, 2016
- Periodic Granulocyte Count Measuring Is Useful for Detecting Asymptomatic Agranulocytosis in Antithyroid Drug-Treated Patients with Graves' DiseaseEuropean Thyroid Journal, 2016
- Analysis of 754 Cases of Antithyroid Drug-Induced Agranulocytosis Over 30 Years in JapanThe Journal of Clinical Endocrinology & Metabolism, 2013
- Antithyroid DrugsNew England Journal of Medicine, 2005
- Retrospective Analysis of 18 Cases of Antithyroid Drug (ATD)-Induced Agranulocytosis.Endocrine Journal, 2002
- Antithyroid Drug–Induced AgranulocytosisArchives of internal medicine (1960), 1990